Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia

NCT05133882 is registered in ClinicalTrials.gov with Sunshine Lake Pharma Co., Ltd. as lead sponsor.

NCT NCT05133882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05133882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ib/II, Multi-center, Open Clinical Trial of Crifortinib Besylate Combined With Chemotherapy in Newly-treated Adult Subjects With Acute Myeloid Leukemia
Lead sponsor
Sunshine Lake Pharma Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
October 31, 2022
Completion date
June 30, 2028
Enrollment
133 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, adult